Supplementary Material

Appendix 1: Searching strategies for CPGs on PICC-related thrombosis prevention in patients

Appendix 2: Excluded studies and reason

Appendix 3: Definitions of AGREE II domains

Appendix 4: Summary of sources where CPGs were obtained

Appendix 5: AGREE II scaled item scores of CPGs for PICC-related thrombosis prevention in patients

Appendix 6: Specific recommendations across all CPGs that informed in Table 4

Appendix 7: Evidence level systems used across CPGs

Supplementary Figure 1 The AGREE II domain scores of each guideline

Page 1 of 25

Appendix 1: Searching strategies for CPGs on PICC-related thrombosis prevention in patients

Cochrane Library search performed on 8 August 2024

#	Query
1	MeSH descriptor: [Practice Guideline] explode all trees
2	MeSH descriptor: [Consensus] explode all trees
3	MeSH descriptor: [Practice Patterns, Nurses'] explode all trees
4	MeSH descriptor: [Practice Patterns, Physicians'] explode all trees
5	(practice guideline*):ti,ab,kw OR (clinical guideline*):ti,ab,kw OR (consensus):ti,ab,kw
	OR (practice pattern*):ti,ab,kw OR (best practice*):ti,ab,kw
6	1 OR 2 OR 3 OR 4 OR 5
7	MeSH descriptor: [Venous Thrombosis] explode all trees
8	MeSH descriptor: [Venous Thromboembolism] explode all trees
9	MeSH descriptor: [Upper Extremity Deep Vein Thrombosis] explode all trees
10	(venous thrombo* OR vein thrombo* OR catheter related thrombo* OR CRT OR VTE
	OR UEDVT):ti,ab,kw
11	7 OR 8 OR 9 OR 10
12	MeSH descriptor: [Catheterization, Peripheral] explode all trees
13	(peripherally inserted central catheter*):ti,ab,kw OR (PICC*):ti,ab,kw
14	12 OR 13
15	6 AND 11 AND 14

PubMed search performed on 8 August 2024

	· · · · · · · · · · · · · · · · · · ·
#	Query
1	Search:(((("Practice Guidelines as Topic"Mesh]) OR "Practice Guideline" [Publication
	Type]) OR "Consensus"[Mesh])OR"Practice Patterns, Nurses'"[Mesh]) OR "Practice
	Patterns, Physicians'[Mesh]
2	Search: ((((practice guideline*[Title/Abstract]) OR (clinical guideline*[Title/Abstract]))
	OR (consensus[Title/Abstract])) OR (practice pattern*[Title/Abstract])) OR (best
	practice*[Title/Abstract])
3	1 OR 2
4	Search: (("Venous Thrombosis"[Mesh]) OR "Venous Thromboembolism"[Mesh]) OR
	"Upper Extremity Deep Vein Thrombosis"[Mesh]
5	Search: (((((venous thrombo*[Title/Abstract]) OR (vein thrombo*[Title/Abstract])) OR
	(catheter related thrombo*[Title/Abstract])) OR (CRT[Title/Abstract])) OR
	(VTE[Title/Abstract])) OR (UEDVT[Title/Abstract])
6	4 OR 5
7	Search: "Catheterization, Peripheral"[Mesh]
8	Search: (peripherally inserted central catheter*[Title/Abstract]) OR
	(PICC*[Title/Abstract])
9	7 OR 8
10	3 AND 6 AND 9

EMBASE search performed on 8 August 2024

#	Query
1	'practice guideline'/exp OR 'consensus'/exp OR 'nursing practice'/exp OR 'clinical
	practice'/exp
2	'practice guideline*':ab,ti OR 'clinical guideline*':ab,ti OR consensus:ab,ti OR 'clinical
	practice':ab,ti OR 'best practice*':ab,ti OR 'nursing practice':ab,ti
3	1 OR 2
4	'vein thrombosis'/exp OR 'venous thromboembolism'/exp OR 'catheter thrombosis'/exp
5	'venous thrombo*':ab,ti OR 'vein thrombo*':ab,ti OR 'catheter related thrombo*':ab,ti OR
	crt:ab,ti OR vte:ab,ti OR 'upper extremity deep vein thrombosis':ab,ti OR uedvt:ab,ti
6	4 OR 5
7	'peripherally inserted central venous catheter'/exp
8	'peripherally inserted central catheter*':ab,ti OR picc*:ab,ti
9	7 OR 8
10	3 AND 6 AND 9

CINAHL search performed on 8 August 2024

#	Query
1	(MH "Practice Guidelines") OR (MH "Consensus")
2	TI (practice guideline* OR clinical guideline* OR consensus OR clinical practice OR
	best practice* OR nursing practice) OR AB (practice guideline* OR clinical guideline*
	OR consensus OR clinical practice OR best practice* OR nursing practice)
3	1 OR 2
4	(MH "Venous Thromboembolism") OR (MH "Venous Thrombosis") OR (MH
	"Catheter-Related Thrombosis") OR (MH "Upper Extremity Deep Vein Thrombosis")
5	TI (venous thrombo* OR vein thrombo* OR catheter related thrombo* OR CRT OR
	VTE OR UEDVT) OR AB (venous thrombo* OR vein thrombo* OR catheter related
	thrombo* OR CRT OR VTE OR UEDVT)
6	4 OR 5
7	(MH "Peripherally Inserted Central Catheters")
8	TI (peripherally inserted central catheter* OR PICC*) OR AB (peripherally inserted
	central catheter* OR PICC*)
9	7 OR 8

10 3 AND 6 AND 9

CNKI search performed on 8 August 2024

#	Query
1	(主题: '静脉血栓栓塞症'+'深静脉血栓'+'导管相关性血栓') AND (主题: '外周穿
	刺中心静脉导管'+'外周中心静脉导管置管'+'中心静脉通路装置'+'PICC')
	AND (主题: '指南'+'共识')
2	Language=中文
3	1 AND 2

Page 3 of 25

WanFang search performed on 8 August 2024

#	Query
1	题名或关键词:(静脉血栓栓塞症 or 深静脉血栓 or 导管相关性血栓) and 题名
	或关键词: (外周穿刺中心静脉导管 or 外周中心静脉导管置管 or 中心静脉通
	路装置 or PICC) and 题名或关键词: (指南 or 共识)
2	语言:中文
3	1 AND 2

Page 4 of 25

Appendix 2: Excluded studies and reason

	Author (year)	Title	Reason(s) for exclusion
1	Bierman S. (2016)	AAGBI safe vascular access guidelines II	This is an interpretation of a guideline on PICC-related
			thrombosis, not a guideline.
2	Brewer C. (2012)	Reducing upper extremity deep vein	This is a less normative summary of evidence on
		thrombosis when inserting PICCs	reducing PICC-associated thrombosis, not a guideline.
3	Delluc A, et al. (2015)	Catheter-related thrombosis: Unresolved	This is a review summarizing the unresolved issues of
		issues	catheter-related thrombosis, not a guideline.
4	International Society on	Catheter-associated deep vein thrombosis	Provides guidance for the prevention of catheter-related
	Thrombosis and Haemostasis,	of the upper extremity in cancer patients:	thrombosis in cancer patients, not a guideline.
	ISTH (2014)	guidance from the SSC of the ISTH	
5	Evans RS, et al. (2013)	Reduction of peripherally inserted central	This is a single-center study of
		catheter-associated DVT	catheter-versus-PICC-associated thrombosis, not
			prevention, and is not a guideline.
6	J A Capdevila (2016)	2016 Expert consensus document on	
		prevention, diagnosis and treatment of	-
		short-term peripheral venous	registration, and diagnosis and treatment of
		catheter-related infections in adult	catheter-related infections. It was excluded due to the
			absence of content dealing with catheter-related
			thrombosis.
7	Macmillan T, et al. (2018)	SecurAcath for Securing Peripherally	_
		Inserted Central Catheters: A NICE	Technology Guidance summaries. It is not a guideline.
		Medical Technology Guidance	
8	Maynard G. (2014)	Upper extremity deep vein thrombosis: A	This is a review of catheter-related deep venous

Page 5 of 25

		call to arms	thrombosis of the upper extremity, not a guideline.
9	Meyer M B (2011)	Managing Peripherally Inserted Central	This is a retrospective study of PICC-associated
		Catheter Thrombosis Risk: A Guide for	thrombosis. It is not a guideline.
		Clinical Best Practice	
10	Infusion Nursing Society, INS	Infusion Therapy Standards of Practice, 8th	An updated version is available.
	(2021)	Edition	
11	American Society of	Practice Guidelines for Central Venous	This recommendation for prevention of catheter-related
	Anesthesiologists, ASA (2019)	Access 2020: An Updated Report by the	infections and mechanical trauma or injury does not
		American Society of Anesthesiologists	address catheter-related thrombosis.
		Task Force on Central Venous Access.	
12	ASCO (2019)	Venous Thromboembolism Prophylaxis	For Venous Thromboembolism Prophylaxis and
		and Treatment in Patients With Cancer:	Treatment in Patients With Cancer, catheter-related
		ASCO Clinical Practice Guideline Update	thrombosis was not involved.
13	American Society of	American Society of Hematology 2018	This article mainly focuses on the drug prevention of
	Anesthesiologists, ASA (2018)	guidelines for management of venous	VTE in hospitalized and non-hospitalized medical
		thromboembolism: prophylaxis for	patients, and does not involve the content of
		hospitalized and nonhospitalized medical	catheter-related thrombosis.
		patients	
14	International Initiative on	International clinical practice guidelines	An updated version is available.
	Thrombosis and Cancer,	for the treatment and prophylaxis of	
	ITAC-CME (2013)	thrombosis associated with central venous	
		catheters in patients with cancer	
15	National Institute for Health and	Venous thromboembolic diseases:	The diagnosis and management of VTE are not
	Care Excellence, NICE (2020)	diagnosis, management and thrombophilia	concerned with the prevention of catheter-associated
		testing	thrombosis.
16	American Society of	American Society of Hematology 2018	The diagnosis of VTE is described only, but

	Anesthesiologists, ASA (2018)	guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism	catheter-related thrombosis is not mentioned.
17	American Society of Anesthesiologists, ASA (2019)	American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients	For prevention of vte in hospitalized patients surgeons not involved catheter-related thrombosis.
18	Chinese Society of Clinical Oncology, CSCO (2019)	Tumor related prevention and treatment guidelines for venous thromboembolism (2019 edition)	Prophylaxis of catheter-related thrombosis was not covered.
19	Fu QN, et al. (2020)	Clinical Practice Recommendation of Chinese Expert Consensus on Venous Thrombosis associated with Infusion catheterization	This article is a guide interpretation.
20	ClinicalPracticeGuidelines(CanadianMedicalAssociation)(2020)	Central venous catheter-related deep vein thrombosis	This article provides guidance for the prevention of catheter-related thrombosis and is not a guideline .

Page 7 of 25

Appendix 3: Definitions of AGREE II domains

Domain 1 - Scope and Purpose: This domain is concerned with the overall aim(s) of the guideline, the specific health question(s) it attempts to address, and the target population(s) that the guideline focusses on (items 1-3).

Domain 2 - Stakeholder Involvement: This domain focuses on the extent to which the guideline was developed by the appropriate stakeholders and consequently, how well the guideline represents the views of its' intended users (items 4-6).

Domain 3 - Rigour of Development: This domain relates to the processes used to gather and synthesize evidence that underpins the guideline, the methods used to formulate recommendations, and the process for updating the guideline (items 7-14).

Domain 4 - Clarity of Presentation: This domain focusses on the language, structure, and format of the guideline (items 15-17).

Domain 5 - Applicability: This domain pertains to the likely barriers and facilitators to guideline implementation, strategies to improve and monitor guideline uptake, and the resource implications of applying the guideline (item 18-21).

Domain 6 - Editorial Independence: This domain is concerned with the formulation of recommendations not being unduly biased with competing for interest, such as funding, personal gain or ghost writing (items 22-23).

Overall assessment: This is a rating of the overall quality of the guideline, based on the judgement of guideline appraisers, and dictates whether the appraiser would recommend the use of the guideline in practice.

Page 8 of 25

Appendix 4: Summary of sources where CPGs were obtained

2013-american-society-clinical-oncology-clinical-practiceASHhttps://www-ncbi-nlm-nih-gov-443.webvpn.cams.cn/pmc/articles/PMC79032021232/pdf/advancesADV2020003442C.pdfINShttps://www-embase-com-443.webvpn.cams.cn/search/results?subaction=vi2021ewrecord&id=L633948335&from=exportCCC-Ihttps://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03UA2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-ITTC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	CPG	Link to document
ASCO ASCO https://guidelines.ebmportal.com/central-venous-catheter-care-patient-cancer -american-society-clinical-oncology-clinical-practiceASH https://www-ncbi-nlm-nih-gov-443.webvpn.cams.cn/pmc/articles/PMC7903 2021 232/pdf/advancesADV2020003442C.pdfINS https://www-embase-com-443.webvpn.cams.cn/search/results?subaction=vi ewrecord&id=L63394835&from=exportCCC-I LOC-I UA 2020CMA bttps://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03UA 2020CMA bttps://ss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx 2018IITC- https://rs.yiigle.com/cmaid/1410887CNA 2022ITAC- bttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(22)05263-1CME 2013ESMO bttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(2015	Docu	
2013-american-society-clinical-oncology-clinical-practiceASHhttps://www-ncbi-nlm-nih-gov-443.webvpn.cams.cn/pmc/articles/PMC79032021232/pdf/advancesADV2020003442C.pdfINShttps://www-embase-com-443.webvpn.cams.cn/search/results?subaction=vi2021ewrecord&id=L633948335&from=exportCCC-Ihttps://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03UA2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-ITTC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	ment	
ASHhttps://www-ncbi-nlm-nih-gov-443.webvpn.cams.cn/pmc/articles/PMC79032021232/pdf/advancesADV2020003442C.pdfINShttps://www-embase-com-443.webvpn.cams.cn/search/results?subaction=vi2021ewrecord&id=L633948335&from=exportCCC-Ihttps://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03UA2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	ASCO	https://guidelines.ebmportal.com/central-venous-catheter-care-patient-cancer
2021232/pdf/advancesADV2020003442C.pdfINShttps://www-embase-com-443.webvpn.cams.cn/search/results?subaction=vi2021ewrecord&id=L633948335&from=exportCCC-Ihttps://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03UA2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	2013	-american-society-clinical-oncology-clinical-practice
INShttps://www-embase-com-443.webvpn.cams.cn/search/results?subaction=vi2021ewrecord&id=L633948335&from=exportCCC-Ihttps://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03UA2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	ASH	https://www-ncbi-nlm-nih-gov-443.webvpn.cams.cn/pmc/articles/PMC7903
2021ewrecord&id=L633948335&from=exportCCC-Ihttps://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03UA2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	2021	232/pdf/advancesADV2020003442C.pdf
CCC-Ihttps://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03UA2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	INS	https://www-embase-com-443.webvpn.cams.cn/search/results?subaction=vi
UA2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	2021	ewrecord&id=L633948335&from=export
2020CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	CCC-I	https://link.cnki.net/doi/10.19538/j.cjps.issn1005-2208.2020.04.03
CMAhttps://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx2018IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	UA	
2018IITC- CNA 2022ITAC- https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME 22)05263-1CME 2013ESMO 2015https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(2015	2020	
IITC-https://rs.yiigle.com/cmaid/1410887CNA2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	СМА	https://oss.wanfangdata.com.cn/file/download/perio_zhyx201836002.aspx
CNA 2022ITAC- https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME 22)05263-12013ESMO 2015https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	2018	
2022ITAC-https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	IITC-	https://rs.yiigle.com/cmaid/1410887
ITAC- CMEhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(201322)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	CNA	
CME22)05263-12013ESMOhttps://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(201519)47179-2	2022	
2013ESMO201519)47179-2	ITAC-	https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S1538-7836(
ESMO https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(2015 19)47179-2	CME	22)05263-1
2015 19)47179-2	2013	
	ESMO	https://linkinghub-elsevier-com-s.webvpn.cams.cn/retrieve/pii/S0923-7534(
ISCC https://www.nchi.nlm.nih_gov_443 webypp came cn/pmc/articles/PMC7085	2015	19)47179-2
1300 1000	ISCC	https://www-ncbi-nlm-nih-gov-443.webvpn.cams.cn/pmc/articles/PMC7085
M 816/pdf/ijccm-24-S6.pdf	М	
2020	2020	

CPGs, clinical practice guidelines; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; INS, Infusion Nursing Society; CCC-IUA, Chinese Chapter Congress of the International Union of Angiology; CMA, China Medical Association; IITC-CNA, Intravenous Infusion Therapy Committee of Chinese Nursing Association; ITAC-CME, International Initiative on Thrombosis and Cancer; ESMO, European Society for Medical Oncology; ISCCM, Indian Society of Critical Care Medicine.

Section	Item	ASC	O	ASH	[INS		CCC-	IUA	CM	4	IITC-	CNA	ITAC	-CM	ESM	0	ISC	СМ
		2013	;	2021		2024	ļ	2020		2018	5	2022		E 202	2	2015		2020)
		A1	A2	A1	A2	A1	A2	A1	A2	A1	A2	A1	A2	A1	A2	A1	A2	A1	A2
Scope and	1	7	7	7	7	7	7	6	7	7	7	7	7	7	7	5	6	7	7
Purpose	2	7	7	7	7	7	7	6	5	7	7	6	6	6	7	6	6	6	5
	3	7	7	7	7	7	7	7	7	6	7	6	6	7	7	7	7	7	7
Stakeholder	4	7	5	7	7	7	7	7	7	7	7	5	5	7	7	7	7	7	7
Involvemen	5	5	4	5	6	2	1	2	1	2	2	1	2	5	5	2	2	2	2
	6	7	7	7	7	7	7	6	7	7	6	7	7	7	7	5	4	7	7
Rigour of	7	5	6	5	4	7	7	2	1	7	7	7	7	7	7	2	1	7	7
Development	8	6	6	2	2	2	1	2	4	4	2	1	2	5	6	2	3	2	1
	9	2	1	7	7	6	5	2	2	7	7	7	7	7	7	7	7	5	6
	10	6	5	7	7	7	7	3	4	7	7	7	7	7	7	6	6	6	6
	11	6	5	7	7	7	7	6	6	7	7	6	6	7	7	7	7	7	7
	12	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7
	13	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7
	14	7	7	6	4	7	7	2	1	7	7	1	1	5	6	2	1	2	1
Clarity of	15	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7
Presentation	16	6	7	7	6	6	7	7	7	7	7	6	7	7	6	7	7	7	7
	17	6	5	7	7	7	7	7	6	6	5	5	6	7	7	7	6	7	6
Applicability	18	7	7	5	6	7	7	4	3	4	3	4	3	4	3	3	4	3	4
	19	4	3	7	7	7	7	2	2	7	7	5	6	6	7	2	2	7	7
	20	7	7	7	7	4	5	6	6	6	5	4	5	7	7	6	6	6	5
	21	2	2	7	7	5	6	2	4	2	4	2	2	2	2	2	3	7	7
Editorial	22	7	7	7	6	6	6	7	7	6	5	7	7	6	6	7	7	7	7
Independence	23	7	7	7	7	7	7	5	6	7	7	6	6	7	7	7	7	7	7
Overall	OA1	6	6	6	6	6	7	4	4	6	6	5	5	6	6	4	5	6	6
Assessment	OA2	Yes	Yes	Yes	Yes	Yes	Yes	Yes*	Yes*	Yes	Yes	Yes*	Yes*	Yes	Yes	Yes*	Yes*	Yes	Yes

Appendix 5: AGREE II scaled item scores of CPGs for PICC-related thrombosis prevention in patients

*Recommended with modifications.

Page 10 of 25

Appendix 6: Specific recommendations across all CPGs that informed in Table 4

Recommendations		ations	Corresponding recommendation from each of the included CPGs									
identified in Table 4		Table 4										
1. Id	lentify	Patient	<u>INS 2024:</u>									
risk fa	actors		 Malignancy (type of cancer, tumor size, and characteristics), diabetes mellitus, obesity, chemotherapy administration, thrombophilia (eg, Factor V Leiden, protein C deficiency, protein S deficiency), critical illness, and personal and family history of thrombosis. (I) Other risk factors include SARS-CoV 2 virus infection (COVID-19), patient age (but varies widely per study and population risks), pregnancy, elevated triglycerides, elevated low-density protein, ethnicity (higher risk reported in Black or African Americans), reduced functional capacity (as measured by Eastern Oncology Cooperative Group [ECOG] scoring), readmission to the hospital shortly after central vascular access device (CVAD) insertion, inadequate hydration and nutrition, non-O blood types, and blood transfusions. (I) 									
			CCC-IUA 2020:									
			D Patients with catheterization are often in special disease-related states, and these states are highly overlapping with high risk factors									
			for venous thrombosis, such as surgery, malignant tumors, and prolonged bed rest. (WG)									
			Malignant tumor patient is one of the important people use infusion catheter, malignant tumor. The risk of VTE is significantly									
			increased in patients with malignant tumors, and the risk may be increased by chemotherapy and surgery. (WG)									
2.Iden	ntify cat	heter rela	ted risk factors									
00	Catheter	r	<u>INS 2024:</u>									
d	liameter	r	(Use the smallest diameter, least number of lumens possible to deliver the required infusion therapy. (I)									
S	election	l	 In a meta-analysis of PICC-related outcomes, optimal insertion techniques and use of single-lumen, smaller diameter PICCs reduced PICC-related DVT risk to a rate comparable to other CVADs. (I) Measure the catheter-to-vessel ratio prior to insertion; ensure no more than 45% ratio. (II) 									

Page 11 of 25

	<u>CCC-IUA 2020:</u>
	• On the premise of meeting the treatment needs, the infusion device with the smallest external diameter, the least number of lumen
	and the least trauma should be selected. (WG)
O Catheter tip	<u>INS 2024:</u>
position	• Position the tip of a CVAD in the lower third of the superior vena cava (SVC) or upper third of the right atrium (RA) at or near the
	cavoatrial junction (CAJ) for adults and children. For lower body insertion sites, position the CVAD tip in the inferior vena cava
	(IVC) above the level of the diaphragm. (A/P)
	• For lower body insertion sites, position the CVAD tip in the inferior vena cava (IVC) above the level of the diaphragm. (IV)
	<u>CCC-IUA 2020:</u>
	• Under the same circumstances, the risk of thrombosis is lower if the catheter tip is located in the subclavian vein than in the
	proximal part of the basilic vein. (WG)
	©
	<u>ITAC-CME 2022:</u>
	• Catheters should be inserted on the right side, in the jugular vein, and the distal extremity of the central catheter should be located
	at the junction of the superior vena cava and the right atrium (Grade 1B).
	<u>ISCCM 2020:</u>
	• We recommend IJ and SCV catheter tip should be placed in the lower one-third of the SVC near the SVC/RA junction (A, 2).
3. Identify operator	<u>INS 2024:</u>
risk factors	• Use a bundled approach for PICC insertion, including systematic ultrasound evaluation and identification of optimal area for
	placement, insertion methods that reduce vascular trauma, optimal tip placement verification, optimal catheter-to-vein ratio, and use
	of smallest diameter/fewest number of lumens. (II)
	Consider tunneling PICCs. A single-center, randomized, controlled, nonblinded, prospective trial demonstrated tunneled PICCs had
	a lower incidence of venous thrombosis and lower costs of catheter maintenance compared to nontunneled PICCs. (III)

Page 12 of 25

	• Reduce thrombotic risk with arterial catheter insertion and management through use of ultrasound for accurate insertion,
	optimization of the catheter entry angle and length within the artery, catheter securement and stabilization, and frequent monitoring
	of circulatory status. (V)
	• The use of electrocardiography to confirm appropriate PICC tip positioning has been associated with reduced thrombotic risk. (III)
	<u>CCC-IUA 2020:</u>
	• Repeated puncture and withdrawal of catheter during catheterization can aggravate intimal injury and increase the risk of
	thrombosis. (WG)
	• Non-standard rushed, sealing tube operation can increase the thrombotic wind duct loss risk. (WG)
	<u>ISCCM 2020:</u>
	• We recommend that a mechanism should be in place to assess knowledge and compliance with guidelines of all the personnel
	involved in care related to CVC (A, 1)
4. Risk assessment of	<u>INS 2024:</u>
patients with PICC	• Evaluate the risk of CAT during the process of VAD selection with careful consideration of patient vasculature, urgency and type
	of treatment required, and patient preference and functional needs (including laterality). (I)
	<u>CMA 2018:</u>
	• VTE risk assessment is recommended for patients with a central venous catheter (2B).
5. Consider use of a ris	k scoring system
O Using Caprini	<u>INS 2024:</u>
Risk	• The Caprini Risk Assessment Model may have predictive value for PICC-related thrombosis, especially in high-risk patients. The Caprini
Assessment	score, however, was found to have moderate sensitivity and low specificity, possibly leading to overdiagnosis. (IV)
Model	
© Using Michigan	<u>INS 2024:</u>
Risk Score	Machine learning predictive techniques using genotypes may assist in identifying patients at high risk for PICC-related thrombosis. (IV)

Page 13 of 25

0	Using Khorana	a <u>(</u>	<u>CMA 2018:</u>
	score model	•	D VTE risk assessment using the Khorana score model is recommended for outpatient patients with malignancies receiving
			chemotherapy. (1B)
6. N	Ionitor for signs	and	symptoms
9	Measuring arn	n <u>1</u>	INS 2024:
	circumference		Monitor for signs, symptoms, and potential consequences of CAT; recognize that CA-DVT often does not produce overt signs and
			symptoms. Clinical signs and symptoms are related to obstruction of venous blood flow and may include, but are not limited to,
			pain/edema/erythema in the extremity, shoulder, neck, or chest, and engorged peripheral veins of the extremity. (IV)
		•	D Measure baseline circumference of the extremity with a PICC or a midline catheter upon insertion, noting location for future
			measurements to ensure consistent measurement. Assess circumference when edema or signs and symptoms of DVT present, noting the
			location and characteristics of edema. A 3-cm increase in mid-arm circumference in adults with PICCs was associated with CA-DVT.
			(IV)
		•	Recognize post-thrombotic syndrome as a potential long-term consequence of CA-DVT characterized by chronic pain, swelling, and skin
			changes. (II)
7. P	harmacologic pr	ever	ntative measures for PICC-related thrombosis
9	guided by	y <u>1</u>	INS 2024:
	individual	•	Recommendations for prophylactic anticoagulation for CA-DVT prevention have not been established for all patient populations but
	patient risk		should be guided by individual patient risk. (I)
			a. VTE prophylaxis is recommended during cancer treatment requiring CVAD insertion and has not been associated with a risk of major
			bleeding. (I)
			b. The role of pharmacologic VTE prophylaxis is unclear in pediatric patients but has been associated with decreased CAT risk without
			increased bleeding risk in specific pediatric populations. (II)
9	Not to use a	s A	<u>ASCO 2013:</u>
	preference	•	The use of systemic anticoagulation (war-farin, low-molecular weight heparin [LMWH], or unfractionated heparin) has not been
			shown to decrease the incidence of catheter- associated thrombosis, and therefore, routine prophylaxis with anti- coagulants is not
			recommended for patients with cancer with CVCs. (WG)
L			

Page 14 of 25

		 ASH 2021: • For patients with cancer and a central venous catheter (CVC), the ASH guideline panel suggests not using parenteral thromboprophylaxis (conditional recommendation, low certainty in the evidence of effects ⊕⊕OO). • For patients with cancer and a CVC, the ASH guideline panel suggests not using oral thromboprophylaxis (conditional recommendation, low certainty in the evidence of effects ⊕⊕OO). • For patients with cancer and a CVC, the ASH guideline panel suggests not using oral thromboprophylaxis (conditional recommendation, low certainty in the evidence of effects ⊕⊕OO). • For patients with cancer and a CVC, the ASH guideline panel suggests not using oral thromboprophylaxis (conditional recommendation, low certainty in the evidence of effects ⊕⊕OO). • CMA 2018: • Routine pharmacologic prophylaxis is not recommended for low-risk patients (2B).
		<u>ITAC-CME 2022:</u>
		 Use of anticoagulation for routine prophylaxis of catheter-related thrombosis is not recommended (Grade 1A).
0	Use LMWH or	<u>CMA 2018:</u>
	LDUH as	Medium and high risk patients without anticoagulation taboo, suggest using LMWH or LDUH (2 B).
	preference	
8. N	lon-pharmacologic	al preventative measures for PICC-related thrombosis
0	handgrip	<u>INS 2024:</u>
	exercise	Consider upper extremity exercise to reduce venous stasis; handgrip exercise using an elastic ball 3 or 6 times per day for 3 weeks was
		associated with a lower incidence of ultrasound-confirmed CA-DVT in patients with cancer who had a PICC. Further research is needed to
		identify postinsertion nursing interventions that reduce thrombotic risk (III).
		 <u>CCC-IUA 2020:</u> When conditions permit, the use of nonpharmacological measures for thromboprophylaxis is encouraged, including early mobilization of the catheterization limb, normal daily activities, appropriate limb exercise, and adequate hydration. (WG)
		<u>IITC-CNA 2022:</u>

Page 15 of 25

		Physical prophylaxis can be used to reduce thrombosis, and the use of non-pharmacological measures to prevent thrombosis is encouraged
		when conditions permit (V, B).
0	flushing with	<u>ASCO 2013:</u>
	saline as	• Routine flushing with saline of the CVC to prevent fibrin buildup is recommended. (WG)
	preference	
		<u>ESMO 2015:</u>
		1 Intermittent flushing with heparin is a standard practice in the maintenance of CVC patency. However, when compared with 0.9%
		normal saline flushing, no differences in thrombosis rates were found (I, C)
0	providing	<u>ISCCM 2020:</u>
	appropriate and	• We suggest providing appropriate and adequate nursing care to improve CVC-related outcomes. (B, 2)
	adequate	
	nursing care	<u>CCC-IUA 2020:</u>
		• For patients with high risk of thrombosis, it is still necessary to take corresponding preventive measures against VTE risk. (WG)
		<u>IITC-CNA 2022:</u>
		• The principles of aseptic operation should be strictly adhered to during puncture and maintenance to reduce the chance of central venous
		catheter infection (II, A).
9. D	iagnose and confir	m PICC-related thrombosis
0	Doppler	<u>INS 2024:</u>
	ultrasound as	• Diagnose and confirm CA-DVT using color-flow Doppler ultrasound by the presence of at least 2 of the following: an echogenic
	preference	mass in the venous structure assessed; noncompressibility of the vein, abnormal color Doppler vein pattern, and/or vein filling
		defect. Venography with contrast injection may also be used to assess more proximal veins (eg, brachiocephalic) that are obscured
		by the clavicle or ribs. (II)
		<u>CC-IUA 2020:</u>
		O Doppler ultrasound is the first choice, which can indicate the location and range of CRT. (WG)

Page 16 of 25

		 ESMO 2015: Although venography is considered the gold standard for the diagnosis of CRT, Doppler ultrasound is usually carried out (III, A). ISCCM 2020: We suggest that ultrasound guidance can be used for early identification of mechanical complication (B, 2). IITC-CNA 2022:
		 The occurrence of catheter-related venous thrombosis can be assessed by observation, measurement and questioning of the patient's
		complaints and by colour Doppler imaging methods (I, A).
0	Not to routine	<u>IITC-CNA 2022:</u>
	use Doppler	• Based on the available evidence, the use of Doppler ultrasound to screen all patients for catheter-related venous thrombosis is not
	ultrasound	recommended (IV, D).
10.	Remove the PICC a	against
0	Do not remove	<u>INS 2024:</u>
	catheter unless	• Evaluate the need and appropriateness of PICC exchange. PICC exchange was independently associ- ated with a twofold greater
	necessary	risk of thrombosis in a retrospective study. However, this risk may have been influenced by the fact that patients who experienced
		exchanges were more likely to have had multilumen PICCs. (IV)
		• Do not remove a CVAD in the presence of CA-DVT when the catheter is correctly positioned, functional, and necessary for
		infusion therapy. The decision to remove a CVAD should be made based on the individual patient's characteristics, symptoms, and
		imaging. (I)
		• Carefully consider the need to retain or remove an implanted port at the conclusion of chemotherapy, evaluating the patient risks and need
		for further therapy. (V)
		ISCCM 2020:
		• We recommend prompt removal of CVC when it is not essential (A, 2).
L		

Page 17 of 25

ith catheter for treatment, the likelihood of re-establishing venous access, and the progression of the thrombus (II, B). 11. Treatment after diagnosis Image: Anticoagulation therapy was given for at least 3 months after diagnosis. For CVADs with a longer dwell time, continue the treatment for as long as the CVAD is in situ; unfractionated heparin infusion or catheter-directed thrombolysis may be benefit to patients with severe symptoms. (IV) after extubation ITAC-CME 2022: Image: For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). ITTC-CNA 2022: Image: When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) Iterventions ITTC-CNA 2022: Image: Stablishing After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriat interventions (I, A).			
the catheter for treatment, the likelihood of re-establishing venous access, and the progression of the thrombus (II, B). 11. Treatment after diagnosis • Anticoagulation therapy was given for at least 3 months after extubation • For at least 3 months after extubation • O For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). • IITC-CNA 2022: • • • When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus a ultrasound screening for thrombus before removal (IV, B) • • • • • • • • • • • • • • •			<i>IITC-CNA 2022:</i>
11. Treatment after diagnosis • Anticoagulation therapy was given for at least 3 months after extubation INS 2024: • Treat CA-DVT with anticoagulant medication for at least 3 months after diagnosis. For CVADs with a longer dwell time, continu the treatment for as long as the CVAD is in situ; unfractionated heparin infusion or catheter-directed thrombolysis may be benefit to patients with severe symptoms. (IV) <i>ITAC-CME 2022:</i> • For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). <i>IITC-CNA 2022:</i> • When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus ar ultrasound screening for thrombus before removal (IV, B) • for appropriate interventions • After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriate interventions (I, A). • Establishing <u>CCC-IUA 2020:</u>			• Symptomatic thrombosis should be retained or the timing of extubation should be considered in the light of the degree of dependence on
 Anticoagulation therapy was given for at least 3 months after diagnosis. For CVADs with a longer dwell time, continue the treatment for as long as the CVAD is in situ; unfractionated heparin infusion or catheter-directed thrombolysis may be benefit to patients with severe symptoms. (IV) <i>ITAC-CME 2022:</i> For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). <i>IITC-CNA 2022:</i> When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) for appropriate interventions After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriate interventions (I, A). Medical personnel training <u>CCC-IUA 2020:</u> 			the catheter for treatment, the likelihood of re-establishing venous access, and the progression of the thrombus (II, B).
therapy was	11.	Treatment after dia	agnosis
given for at least 3 months after extubation the treatment for as long as the CVAD is in situ; unfractionated heparin infusion or catheter-directed thrombolysis may be benefit to patients with severe symptoms. (IV) <i>ITAC-CME 2022:</i> • For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). <i>IITC-CNA 2022:</i> • • When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) • <i>IITC-CNA 2022:</i> • • • After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriat interventions <i>IITC-CNA 2022:</i> • • After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriat interventions (I, A). 12. Medical personnel training <i>CCC-IUA 2020:</i>	0	Anticoagulation	<u>INS 2024:</u>
least 3 months after extubation benefit to patients with severe symptoms. (IV) Image: TAC-CME 2022: Image: TAC-CME 2022: Image: TAC-CME 2022: Image: TAC-CME 2022: Image: TAC-CNA 2020: Image: TAC-CNA 2022: Image: TAC-CNA 202		therapy was	Treat CA-DVT with anticoagulant medication for at least 3 months after diagnosis. For CVADs with a longer dwell time, continue
after extubation ITAC-CME 2022: • For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). IITC-CNA 2022: • • When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) • IITC-CNA 2022: • After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriat interventions (I, A). 12. Medical personnel training CCC-IUA 2020:		given for at	the treatment for as long as the CVAD is in situ; unfractionated heparin infusion or catheter-directed thrombolysis may be of
 Interventions ITAC-CME 2022: For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). ITC-CNA 2022: When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) further assessed for appropriate interventions After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriate interventions (I, A). Medical personnel training Establishing <u>CCC-IUA 2020:</u> 		least 3 months	benefit to patients with severe symptoms. (IV)
 For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). <i>IITC-CNA 2022:</i> When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) for appropriate interventions <i>IITC-CNA 2022:</i> After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriat interventions (I, A). Medical personnel training Establishing 		after extubation	
 minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made this setting (guidance). <i>IITC-CNA 2022:</i> When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) for appropriate interventions <i>IITC-CNA 2022:</i> After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriate interventions (I, A). Medical personnel training <u>CCC-IUA 2020:</u> 			<u>ITAC-CME 2022:</u>
interventions interventions (I, A). 12. Medical personnel training © Establishing CCC-IUA 2022: © CC-IUA 2022: Comparison			• For the treatment of symptomatic catheter-related thrombosis in patients with cancer, anticoagulant treatment is recommended for a
IITC-CNA 2022: Image: Constraint of the system of			minimum of 3 months; in this setting, LMWHs are suggested. Direct comparisons between LMWHs and VKAs have not been made in
• When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) • further assessed for appropriate interventions IITC-CNA 2022: • After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriate interventions (I, A). 12. Medical personnel training • Establishing			this setting (guidance).
• When catheter removal is warranted, it should be preceded by routine anticoagulation according to the occurrence of thrombus an ultrasound screening for thrombus before removal (IV, B) • further assessed for appropriate interventions <u>IITC-CNA 2022:</u> • After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriate interventions (I, A). 12. Medical personnel training • Establishing			
• ultrasound screening for thrombus before removal (IV, B) • further assessed for appropriate interventions IITC-CNA 2022: • After thrombosis has occurred, the patient's risk factors for catheter-related venous thrombosis should be further assessed for appropriate interventions (I, A). 12. Medical personnel training <u>CCC-IUA 2020:</u>			
 further assessed for appropriate interventions 12. Medical personnel training CCC-IUA 2020: 			
for appropriate interventions ••••••••••••••••••••••••••••••••••••			
interventions interventions (I, A). 12. Medical personnel training © Establishing <u>CCC-IUA 2020:</u>	Ø	further assessed	
12. Medical personnel training • Establishing <u>CCC-IUA 2020:</u>			
© Establishing <u>CCC-IUA 2020:</u>		interventions	interventions (I, A).
	12.	Medical personnel	training
education and 🛛 Standardized placement, use and maintenance of catheters and professional nursing teams are important prerequisites to redu	0	Establishing	<u>CCC-IUA 2020:</u>
		education and	• Standardized placement, use and maintenance of catheters and professional nursing teams are important prerequisites to reduce
training systems catheter-related complications, including thrombosis. (WG)		training systems	catheter-related complications, including thrombosis. (WG)

Page 18 of 25

		<u>ISCCM 2020:</u>
		• We recommend that a healthcare education and training program should be in place wherever CVCs are inserted and maintained for
		overall quality improvement (A, 1)
0	Establishing	<u>INS 2024:</u>
	Credentialing	• Ensure that the selected VAD is inserted by staff with specific training, using vascular visualization. (II)
	process	
		<u>ISCCM 2020:</u>
		• We suggest providing appropriate and adequate nursing care to improve CVC-related outcomes (B, 2)

CVADs, Central Venous Access Devices; CA-DVT, catheter-associated deep vein thrombosis; CPGs, clinical practice guidelines; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; INS, Infusion Nursing Society; CCC-IUA, Chinese Chapter Congress of the International Union of Angiology; CMA, China Medical Association; IITC-CNA, Intravenous Infusion Therapy Committee of Chinese Nursing Association; ITAC-CME, International Initiative on Thrombosis and Cancer; ESMO, European Society for Medical Oncology; ISCCM, Indian Society of Critical Care Medicine.

Page 19 of 25

Appendix 7: Evidence level systems used across CPGs

Evidence Levels	CPG Working Group
	ASCO 2013/ CCC-IUA 2020
WG	Recommendations based on expert opinion/consensus by the working group.
	ASH 2021
strong	-For patients: most individuals in this situation would want the recommended course of action, and only a small proportion would not.
	-For clinicians: most individuals should follow the recommended course of action. Formal decision aids are not likely to be needed to help individual patients make decisions consistent with their values and preferences.
	-For policy makers: the recommendation can be adopted as policy in most situations. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator.
	-For researchers: the recommendation is supported by credible research or other convincing judgments that make additional research unlikely to alter the recommendation. On occasion, a strong recommendation is based on low or very low certainty in the evidence. In such instances, further research may provide important information that alters the recommendations.
conditional	-For patients: the majority of individuals in this situation would want the suggested course of action, but many would not. Decision aids may be useful in helping patients to make decisions consistent with their individual risks, values, and preferences.
	-For clinicians: recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with their values and preferences. Decision aids may be useful in helping individuals to make decisions consistent with their individual risks, values, and preferences.
	-For policy makers: policymaking will require substantial debate and involvement of various stakeholders. Performance measures about the suggested course of action should focus on whether an appropriate decision-making process is duly documented.
	-For researchers: this recommendation is likely to be strengthened (for future updates or adaptation) by additional research. An evaluation of the conditions and criteria (and the related judgments, research evidence, and additional considerations) that determined the conditional (rather than strong) recommendation will help to identify possible research gaps.

Page 20 of 25

	INS 2024		
Ι	Meta-analysis, systematic literature review, guideline based on randomized controlled trials (RCTs), or at least 3 well-designed RCTs.		
II	Two well-designed RCTs, 2 or more well-designed, multicenter clinical trials without randomization, or systematic literature review of varied prospective study designs.		
III	One well-designed RCT, several well-designed clinical trials without randomization, or several studies with quasi-experimental designs focused on the same question. Includes 2 or more well-designed laboratory studies.		
IV	Well-designed quasi-experimental study, case control study, cohort study, correlational study, time series study, systematic literature review of descriptive and qualitative studies, narrative literature review, or psychometric study. Includes 1 well-designed laboratory study.		
V	Clinical article, clinical/professional book, consensus report, case report, guideline based on consensus, descriptive study, well-designed quality improvement project, theoretical basis, recommendations by accrediting bodies and professional organizations, or manufacturer recommendations for products or services. This also includes a standard of practice that is generally accepted but does not have a research basis (eg, patient identification).		
A/P	Evidence from anatomy, physiology, and pathophysiology as understood at the time of writing.		
Committee Consensus	Review of evidence, discussion, and committee agreement for a Practice Recommendation. Used when there is insufficient or low-quality evidence to draw a conclusion.		
	CMA 2018		
High (A)	Further research is very unlikely to change our confidence in the estimate of effect		
Moderate (B)	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate		
Low (C)	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate		
Very low (D)	Any estimate of effect is very uncertain		
Recommendation (1)	Interventions clearly have more benefits than harms		
Suggestions (2)	Interventions may have more benefits than harms		
Not suggestions	Interventions may do more harm than good or pros and cons of relationship is not clear		

Page 21 of 25

(2)	
Not	Interventions clearly do more harm than good
recommended (1)	
	ITAC-CME 2022
High (A)	further research is very unlikely to change our confidence in the estimate of effect
Moderate (B)	further research is likely to have an important impact on our confidence in the estimate of effect and could change the estimate
Low (C)	further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low (D)	any estimate of effect is very uncertain
Strong (Grade 1)	The panel is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects
Weak (Grade 2)	The panel concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but is not
	confident
Best clinical	In the absence of any clear scientific evidence and because of undetermined balance between desirable and undesirable effects, judgment was
practice	based on the professional experience and consensus of the international experts within the working group
(Guidance)	
	IITC-CNA 2022
Ι	Meta-analysis, systematic literature review, guideline based on randomized controlled trials (RCTs), or at least 3 well-designed RCTs.
II	Two well-designed RCTs, 2 or more well-designed, multicenter clinical trials without randomization, or systematic literature review of varied
	prospective study designs.
III	One well-designed RCT, several well-designed clinical trials without randomization, or several studies with quasi-experimental designs
	focused on the same question.
	Includes 2 or more well-designed laboratory studies.
IV	Well-designed quasi-experimental study, case control study, cohort study, correlational study, time series study, systematic literature review
	of descriptive and qualitative studies, narrative literature review, or psychometric study.
	Includes 1 well-designed laboratory study.
V	Clinical article, clinical/professional book, consensus report, case report, guideline based on consensus, descriptive study, well-designed
	quality improvement project, theoretical basis, recommendations by accrediting bodies and professional organizations, or manufacturer

Page 22 of 25


		recommendations for products or services.
		This also includes a standard of practice that is generally accepted but does not have a research basis (eg, patient identification).
А		Evidence is highly effective and can be recommended to all clinical staff.
В		Evidence is valid and can be recommended to clinical staff.
С		the evidence is valid under certain conditions and the findings should be applied with caution.
D		Evidence validity is quite limited, valid only within a narrow range, and application is more restricted.
		ESMO 2015
Ι		Evidence from at least one large randomised controlled trial of good methodological quality (low potential for bias) or meta- analyses of
		well-conducted randomised trials without heterogeneity
Π		Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or
		of trials with demonstrated heterogeneity
III		Prospective cohort studies
IV		Retrospective cohort studies or case-control studies
V		Studies without control group, case reports, experts opinions
А		Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
В		Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
С		Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs,), optional
D		Moderate evidence against efficacy or for adverse outcome, generally not recommended
E		Strong evidence against efficacy or for adverse outcome, never recommended
		ISCCM 2020
1		Evidence from ≥1 good quality and well-conducted randomized control trial(s) or meta-analysis of RCT's
2		Evidence from at least 1 RCT of moderate quality, or well-designed clinical trial without randomization; or from cohort or case-controlled
		studies
3		Evidence from descriptive studies, or reports of expert committees, or opinion of respected authorities based on clinical experience
Useful	Practice	Not backed by sufficient evidence; however, a consensus reached by the working group, based on clinical experience and expertise

Page 23 of 25

Point (UPP)	
Grade A	Strong recommendations to do (or not to do) where the benefits clearly outweigh the risk (or vice versa) for most, if not all patients
Grade B	Weak recommendations, where benefits and risk are more closely balanced or are more uncertain

CPGs, clinical practice guidelines; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; INS, Infusion Nursing Society; CCC-IUA, Chinese Chapter Congress of the International Union of Angiology; CMA, China Medical Association; IITC-CNA, Intravenous Infusion Therapy Committee of Chinese Nursing Association; ITAC-CME, International Initiative on Thrombosis and Cancer; ESMO, European Society for Medical Oncology; ISCCM, Indian Society of Critical Care Medicine.

Page 24 of 25



Supplementary Figure 1 The AGREE II domain scores of each guideline

4. Clarity of Presentation

CPGs, clinical practice guidelines; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; INS, Infusion Nursing Society; CCC-IUA, Chinese Chapter Congress of the International Union of Angiology; CMA, China Medical Association; IITC-CNA, Intravenous Infusion Therapy Committee of Chinese Nursing Association; ITAC-CME, International Initiative on Thrombosis and Cancer; ESMO, European Society for Medical Oncology; ISCCM, Indian Society of Critical Care Medicine.

Page 25 of 25